L51. From immunosuppression to selective treatments: The benefit-risk ratio

Presse Medicale

Volumn 42, Issue 4 PART2, 2013, Pages 641-643

  Guillevin, Loïc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANCA ASSOCIATED VASCULITIS; CANCER RISK; CHURG STRAUSS SYNDROME; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIC GRANULOMA; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; LETTER; LOW DRUG DOSE; MICROSCOPIC POLYANGIITIS; NECROTIZING ARTERITIS; PRESCRIPTION; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 84875586674     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.01.046     Document Type: Letter

References (27)

1. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18:2180-2188.
2. Sendi P., Wolf A., Graber P., Zimmerli W. Multiple opportunistic infections after high-dose steroid therapy for giant cell arteritis in a patient previously treated with a purine analog. Scand J Infect Dis 2006, 38:922-924.
3. Bourgarit A., Le Toumelin P., Pagnoux C., Cohen P., Mahr A., Le Guern V., et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005, 84:323-330.
4. Gayraud M., Guillevin L., Le Toumelin P., Cohen P., Lhote F., Casassus P., et al. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44:666-675.
5. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
6. Walsh M., Merkel P.A., Mahr A., Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 2010, 62:1166-1173.
7. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
8. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniene J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44.
9. Pagnoux C., Mahr A., Hamidou M.A., Boffa J.J., Ruivard M., Ducroix J.P., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008, 359:2790-2803.
10. Guillevin L., Pagnoux C., Seror R., Mahr A., Mouthon L., Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011, 90:19-27.
11. Boumpas D., Austin H.A., Vaughan E., Yarboro C., Klippel J., Balow J. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993, 119:366-369.
12. Clowse M.E., Copland S.C., Hsieh T.C., Chow S.C., Hoffman G.S., Merkel P.A., et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res 2011, 63:1777-1781.
13. Pagnoux C., Quéméneur T., Ninet J., Perrodeau E., Diot E., Kyndt X., et al. Treatment of systemic necrotizing vasculitides in patients≥65years old: results of the multicenter randomized CORTAGE trial (Abstract). Presse Med 2013, 10.1016/j.lpm.2013.02.069.
14. Charlier C., Henegar C., Launay O., Pagnoux C., Bérezné A., Bienvenu B., et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009, 68:658-663.
15. Martin-Suarez I., D'Cruz D., Mansoor M., Fernandes A.P., Khamashta M.A., Hughes G.R. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997, 56:481-487.
16. Langford C.A. Chronic immunosuppressive therapy for systemic vasculitis. Curr Opin Rheumatol 1997, 9:41-47.
17. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
18. Sneller M.C. Cystitis, bladder cancer, and myelodysplasia in patients with Wegener's granulomatosis: comment on the article by Reinhold-Keller et al. Arthritis Rheum 2000, 43:2853-2855.
19. Le Guenno G., Mahr A., Pagnoux C., Dhote R., Guillevin L. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011, 63:1435-1445.
20. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361.
21. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717-721.
22. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126-1132.
23. Josselin L., Mahr A., Cohen P., Pagnoux C., Guaydier-Souquières G., Hayem G., et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008, 67:1343-1346.
24. de Menthon M., Cohen P., Pagnoux C., Büchler M., Sibilia J., Detrée F., et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow-up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 2011, 29(1 Suppl. 64):S63-S71.
25. Guillevin L., Pagnoux C., Karras A., Khouatra C., Aumaitre O., Cohen P., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. Arthritis Rheum 2012, S706. (supplement), Abstract 1652.
26. van Oers M., van Glabbeke M., Giurgea L., Klasa R., Marcus R.E., Wolf M., et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010, 28:2853-2858.
27. Tarella C., Passera R., Magni M., Benedetti F., Rossi A., Gueli A., et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011, 29:8142-8144.